Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma

Figure 3 Electrophoretic mobility shift assay of the multidrug resistance related protein-1 promoter region that contained the G-1666A site. A: Analysis was performed in the presence (+) or absence (-) of Hep3B nuclear extract. Each binding reaction contained γ-³²P-labeled -1666G (lanes 2-8) or -1666A (lanes 10-14) probes. A 10-, 50-, or 100-fold (as indicated) excess of unlabeled (cold) -1666A or G oligonucleotides (lanes 6-8, 11, and 12 or 3-5, 13, and 14) were included in the binding reactions as specific competitors. Labeled oligonucleotides incubated without the nuclear extracts were included as negative controls (lanes 1 and 9); B: In the present of Hep3B nuclear extract, 10- or 50-fold more excess of unlabeled -1666G oligonucleotides (lanes 3 and 4) or -1666A oligonucleotides (lanes 5 and 6) or non-specific oligonucleotides (lanes 7 and 8) were used as competitors. Lane 1 was the negative control. Lane 2 indicated the labeled -1666G oligonucleotides incubated with the nuclear extracts only. The asterisks indicated the DNA-protein complex.